Pregnancy in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 8, Issue 5, 1996, Pages 424-429

  Khamashta, Munther A ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; PHOSPHOLIPID ANTIBODY;

AMENORRHEA; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONGENITAL HEART BLOCK; FERTILITY; FETUS MONITORING; FETUS WASTAGE; INTRAUTERINE GROWTH RETARDATION; MYOCARDITIS; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029852813     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199609000-00006     Document Type: Article

References (74)

1. Khamashta MA, Asherson RA: Hughes syndrome: antiphospholipid antibodies move closer to thrombosis in 1994. Br J Rheumatol 1995, 34:493-494. At the Sixth International Symposium on Anti-phospholipid Antibodies, held in Leuven, Belgium in 1994, a formal proposal was made to rename APS "Hughes syndrome."
2. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, Ciruelo E, Gomaz-Reino FJ, Muley R, Garcia-Consuegra J, Pinillos V, Rodriguez-Valverde V; Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995, 34:737-741.
3. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythe-matosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993, 119:366-369.
4. Boumpas DT, Fessier BJ, Austin HA, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995, 123:42-53.
5. Bermas BL, Hill JA: Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995, 38:1722-1732. Excellent in-depth review of the use of immunosuppressive drugs in pregnancy.
6. Wang CL, Wang F, Bosco JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995, 4:11-14.
7. McDermott EM, Powell RJ: Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996, 55:224-229. This study confirmed previous studies showing that the risk of cyclophosphamide-induced menopause in women with SLE is considerable.
8. Haga HJ, D'Cruz DP, Asherson RA, Hughes GRV: Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992, 51:885-888.
9. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GRV: Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991, 1:31-35.
10. Ramos PC, Mendez MJ, Ames PRJ, Khamashta MA, Hughes GRV: Pulse cyclophosphamide in the treatment of neuropyschiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996, 14:295-299.
11. Akil M, Amos RS, Stewart P: Infertility may sometimes be associated with NSAID consumption. Br J Rheumatol 1996, 35:76-78.
12. Jungers P, Dougados M, Pelissier C: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982, 25:618-623.
13. Julkunen HA: Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991, 20:427-433.
14. Julkunen HA, Kaaja R, Friman C: Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993, 32:227-230.
15. Asherson RA, Harris EN, Hughes GRV, Farquharson RG: Complications of oral contraceptives and antiphospholipid antibodies. Arthritis Rheum 1988, 31:575-576.
16. Hunt BJ, Khamashta MA: Management of the Hughes syndrome. Clin Exp Rheumatol 1996, 14:115-117. Succinct review of the treatment of major manifestations of APS.
17. Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GRV, Buchanan NMM: Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996, 35:133-138. This study suggests that SLE tends to flare during pregnancy. Flares are maximal during the second and third trimesters and the puerperium. However, flares are not more severe than in nonpregnant patients.
18. Ramsey-Goldman R, Manzi S, Schilling EM, Kutzer JE, Medsger TA Jr: Lupus activity in pregnant and non-pregnant women [abstract]. Arthritis Rheum 1995, 38(Suppl1):S219.
19. Martinez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarcon-Segovia D: Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus 1996, 5:113-119.
20. Lima F, Buchanan NMM, Khamashta MA, Kerslake S, Hughes GRV: Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995, 25:184-192. This prospective study suggests that lupus patients should not be discourged from becoming pregnant despite the increased risk of obstetric complications, especially in renal and aPL-positive patients. The fetal loss risk can be reduced by close obstetric monitoring.
21. Petri M, Tossounian S: Maternal morbidity of SLE pregnancy: a case control study [abstract]. Lupus 1995, 4(suppl 2):130.
22. Johnson MJ, Petri M, Witter FR, Repke JT: Evaluation of preterm delivery In systemic lupus erythematosus pregnancy clinic. Obstet Gynecol 1995, 86:396-399.
23. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154.
24. Petri M, Howard D, Repke J: Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991, 34:1538-1545.
25. Buchanan NMM, Khamashta MA, Kerslake S, Hunt BJ, Hughes GRV: Practical management of pregnancy in systemic lupus erythematosus. Fetal Mat Med Rev 1993, 5:223-230.
26. Wallace DJ: Antimalarial agents and lupus. Rheum Dis Clin North Am 1994, 20:243-263.
27. Buchanan NMM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GRV: Hydroxychloroquine and lupus pregnancy: a review of a series of 36 cases. Ann Rheum Dis 1996, 55:486-488. Largest recorded series of the use of hydroxychloroquine in pregnancy. No ill effects were observed in mothers or babies.
28. Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988, 15:607-610.
29. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991, 8:174-178.
30. Ostensen M, Ostensen H: Safety of nonsteroidal anti-inflammatory drugs in pregnant patients with rheumatic disease. J Rheumetol 1996, 23:1045-1049.
31. Silver RM, Branch W: Recurrent miscarriage: autoimmune considerations. Clin Obstet Gynecol 1994, 37:745-760.
32. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR: Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992, 80:614-620.
33. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996, 1:131-136. Largest recorded experience of pregnancy in patients with APS. Antithrombotic therapy was effective in reducing fetal loss in these patients.
34. Bewley S, Cooper D, Campbell S: Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre-eclampsia intrauterine growth retardation. Br J Obstet Gynaecol 1991, 98:877-879.
35. Trudinger BJ, Stewart GJ, Cook CM, Connelly A, Exner T: Monitoring lupus anticoagulant-positive pregnancies with umbilical artery flow velocity waveforms. Obstet Gynaecol 1988, 72:215-218.
36. Kerslake S, Morton KE, Versi E, Buchanan NMM, Khamashta M, Baguley E, Braude P, Hughes GRV: Early Doppler studies in lupus pregnancy. Am J Reprod Immunol 1992, 28:172-175.
37. Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S: Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol 1993, 82:970-977.
38. Bewley S, Chard T, Grudzinskas G, Cooper D, Campbell S: Early prediction of uteroplacental complications of pregnancy using Doppler ultrasound, placental function tests and combination testing. Ultrasound Obst Gyn 1992, 2:333-337.
39. Silver RM, Draper ML, Byme JLB, Ashwood EA, Lyon JL, Branch W: Unexplained elevations of maternal serum alpha-fetoproteln in women with antiphospholipid antibodies: a harbinger of fetal death. Obst Gyn 1994, 83:150-155.
40. Petri M, Ho AC, Patel J, Demers D, Joseph M, Goldman D: Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. J Rheumatol 1995, 22:1365-1368.
41. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, Emlen W: Antiphospholipid antibodies in predicting adverse pregnancy outcome. Ann Intern Med 1994, 120:470-475.
42. Lynch AM, Rutledge JH, Stephens JK, Murphy JR, Marlar RA, Davila GH, Santos ME, Emlen W: Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lupus 1995, 4:365-369. This study assessed the variability of aPL levels in normal pregnancy and the association of aPL at different times in pregnancy with pregnancy complications.
43. 2-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
44. 2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection systems. Am J Obset Gynecol 1995, 172:926-931.
45. 2-glycoprotein I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995, 10:2001-2005.
46. Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM: Histopathological findings in placentae from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991, 41:179-186.
47. Shoenfeld Y, Blank M, Fisnman P: Antiphospholipid syndrome: from the laboratory bench to the patients' bedside. Lupus 1995, 4(suppl 1):33-36. Succint review of animal models of APS.
48. Piona A, La Rosa L, Tincani A, Faden D, Magro G, Grasso S, Nicoletti F, Balestrieri G, Meroni PL: Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand J Immunol 1995, 41:427-432. Persuasive experimental evidence that thrombotic events at the placental level can be instrumental in the pathogenesis of obstetric complications in APS.
49. Suzuki T, Takabayashi K, Ichikawa K, Itou I, Ishiguro N, Yoshiki T, Koike T: Effects of monoclonal anticardiolipin antibody on pregnant mice. J Rheumatol 1996, 23:83-88.
50. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment Am J Obstet Gynecol 1992, 166:1318-1323.
51. Khamashta MA, Hughes GRV: Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995, 7:389-394. A review of the recent advances made in the study of APS.
52. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Rudniki C, Shoenfeld Y: Aspirin modulates Interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 1995, 22:1086-1090.
53. Dahlman TC, Sjoberg HE, Ringertz H: Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994, 170:1315-1320.
54. Barbour LA, Kick SD, Steiner JF, Loverde ME, Heddleston LN, Lear JL, Baron AE, Barton PL: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994, 170:862-869.
55. Dahlman TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperlum in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
56. Smith R, Athanasou NA, Ostlere SJ, Vipond SE: Pregnancy-associated osteoporosis. Q J Med 1995, 88:865-878. Long-term follow-up of 24 patients with pregnancy-associated osteoporosis. Symptoms occurred most often in the first pregnancy, and in most, symptoms improved soon after delivery. Recurrence of symptoms in subsequent pregnancies was rare.
57. Nelson-Piercy C: Low-molecular-weight heparin for prophylaxis of thromboembolic disease during pregnancy. Curr Obstet Med 1995, 3:147-158. Excellent review of the use of low molecular weight heparin in pregnancy.
58. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y: Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 1993, 169:423-426.
59. Shefras J, Farquharson RG: Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol 1996, 65:171-174. Lumbar spine bone density falls during pregnancy in both women who are treated with low molecular weight heparin and those who are not. Breast feeding delays recovery to baseline values until suckling stops.
60. Spinnato JA, Clark AL, Pierangeli SS, Harris EN: Intravenous Immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obsetet Gynecol 1995, 172:690-694.
61. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, Shoenfeld Y: Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995, 22:1068-1074.
62. Dekker GA, Vries JIP, Doelitzsch PM, Huijgens PC, Von Blomberg BME, Jakobs C, Van Geijn HP: Underlying disorders associated with severe early-onset pre-eclampsia. Am J Obstet Gynecol 1995, 173:1042-1048.
63. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994, 343:619-629.
64. North RA, Ferner C, Gamble G, Fairley KF, Kincaid-Smith P: Prevention of pre-eclampsia with heparin and antiplatelet drugs in women with renal disease. Aust NZJ Obstet Gynaecol 1995, 35:357-362.
65. Buyon JP, Waltuck J, Kleinman C, Copel J: In utero Identification and therapy of congenital heart block. Lupus 1995, 4:116-121. Largest recorded series of CHB. Fluorinated steroids may be efficacious after the identification of heart block, especially in patients with associated myocarditis.
66. Waltuck J, Buyon JP: Autoantibody-assoicatad congenital heart block: outcome in mothers and children. Ann Intern Med 1994, 120:544-551.
67. Hubscher O, Batista N, Rivero S, Marietta C, Arriagada M, Boire G, Menard HA, Arana RM: Clinical and serological identification of 2 forms of complete heart block in children. J Rheumatol 1995, 22:1352-1355.
68. Press J, Uziel Y, Laxer RM, Luy L, Hamilton RM, Silverman ED: Long-term outcome of mothers of children with complete congenital heart block. Am J Med 1996, 100:326-332. This interesting study assessed long-term outcome in the mothers of 64 children with CHB. Most of the initially healthy mothers remained well at follow-up.
69. Garcia S, Nascimento JHM, Bonfa E, Levy R, Oliveira SF, Tavares AV, Carvalho ACC: Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994, 93:718-724.
70. Levy RA, Bonfa ED, Garcia S, Tavares A, Oliveira SF, Vianna VTA, Nascimento JHM, Carvalho ACC: Anti-Ro/SSA antibody titers do not correlate with the induction of heart block in an animal model of neonatal lupus [abstract]. Lupus 1995, 4(suppl 2):137.
71. Meyer O, Richiuti V, Haim T, Muller S: Determination of antibodies to linear epitopes of Ro 52 KDA and Ro 60 KDA autoantigens Is helpful to predict mothers at risk for neonatal lupus syndrome [abstract]. Lupus 1995, 4(suppl 2):137.
72. Maddison PJ, Lee L, Reichlin M, Sinclair A, Wasson C, Schemmer G, Reichlin M: Antl-P57: a novel association with neonatal lupus. Clin Exp Immunol 1995, 99:42-48.
73. Orth T, Domer T, Meyer KH, Buschenfelde Z, Mayet WJ: Complete congenital heart block in neonatal lupus erythematosus is associated with Increased autoantibody titers against calreticulin [abstract]. Lupus 1995, 4(suppl 2):137.
74. 1RNP-positive antibodies in fraternal twins: is this a subset of neonatal lupus erythematosus or a new distinct syndrome? J Am Acad Dermatol 1995, 32:858-862.